[{"id":"3e2e40b4-c16d-49eb-bae1-03ff2569d84e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01989598","created_at":"2021-01-18T09:04:23.190Z","updated_at":"2024-07-02T16:36:16.220Z","phase":"Phase 2","brief_title":"Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT01989598","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • uprosertib (LAE003)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 10/30/2013","start_date":" 10/30/2013","primary_txt":" Primary completion: 08/31/2019","primary_completion_date":" 08/31/2019","study_txt":" Completion: 09/28/2020","study_completion_date":" 09/28/2020","last_update_posted":"2022-03-02"},{"id":"a89806c6-9b0b-4bbb-8b9e-09889924d75a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01935973","created_at":"2021-01-18T08:45:27.521Z","updated_at":"2024-07-02T16:36:40.024Z","phase":"Phase 1","brief_title":"Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer","source_id_and_acronym":"NCT01935973","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • uprosertib (LAE003)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 09/30/2013","start_date":" 09/30/2013","primary_txt":" Primary completion: 09/08/2015","primary_completion_date":" 09/08/2015","study_txt":" Completion: 09/08/2015","study_completion_date":" 09/08/2015","last_update_posted":"2020-10-14"},{"id":"18b66265-2074-463d-b800-fb66da926c83","acronym":"","url":"https://clinicaltrials.gov/study/NCT01941927","created_at":"2021-01-18T08:47:35.823Z","updated_at":"2024-07-02T16:36:50.123Z","phase":"Phase 2","brief_title":"Trametinib With GSK2141795 in BRAF Wild-type Melanoma","source_id_and_acronym":"NCT01941927","lead_sponsor":"Adil Daud","biomarkers":" BRAF • NRAS","pipe":" | ","alterations":" BRAF mutation • NRAS mutation • BRAF wild-type • RAS wild-type • NRAS wild-type","tags":["BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • NRAS mutation • BRAF wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • uprosertib (LAE003)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 09/10/2013","start_date":" 09/10/2013","primary_txt":" Primary completion: 10/14/2014","primary_completion_date":" 10/14/2014","study_txt":" Completion: 05/03/2017","study_completion_date":" 05/03/2017","last_update_posted":"2020-02-12"},{"id":"61933566-4ab8-419c-9df4-f846cef73e73","acronym":"","url":"https://clinicaltrials.gov/study/NCT02093546","created_at":"2021-01-18T09:39:40.657Z","updated_at":"2024-07-02T16:36:50.801Z","phase":"Phase 2","brief_title":"Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290","source_id_and_acronym":"NCT02093546","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • uprosertib (LAE003)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 08/13/2004","start_date":" 08/13/2004","primary_txt":" Primary completion: 01/15/2020","primary_completion_date":" 01/15/2020","study_txt":" Completion: 01/15/2020","study_completion_date":" 01/15/2020","last_update_posted":"2020-01-28"},{"id":"09c2a270-153c-423a-994b-9778351a85a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT01964924","created_at":"2021-01-18T08:55:54.221Z","updated_at":"2025-02-25T13:10:55.870Z","phase":"Phase 2","brief_title":"Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT01964924","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":"","alterations":" ","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • uprosertib (LAE003)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 10/02/2013","start_date":" 10/02/2013","primary_txt":" Primary completion: 01/20/2017","primary_completion_date":" 01/20/2017","study_txt":" Completion: 04/23/2018","study_completion_date":" 04/23/2018","last_update_posted":"2019-09-20"},{"id":"944b9c3d-28e3-41aa-9654-590476112dd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT01138085","created_at":"2021-01-18T04:31:28.907Z","updated_at":"2024-07-02T16:37:16.426Z","phase":"Phase 2","brief_title":"Safety, Pharmacokinetics (PK) of AKT and MEK Combination","source_id_and_acronym":"NCT01138085","lead_sponsor":"GlaxoSmithKline","biomarkers":" HER-2 • KRAS • BRAF • ER • PGR • PTEN","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • BRAF wild-type","tags":["HER-2 • KRAS • BRAF • ER • PGR • PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • uprosertib (LAE003)"],"overall_status":"Completed","enrollment":" Enrollment 240","initiation":"Initiation: 05/04/2010","start_date":" 05/04/2010","primary_txt":" Primary completion: 11/19/2014","primary_completion_date":" 11/19/2014","study_txt":" Completion: 11/19/2014","study_completion_date":" 11/19/2014","last_update_posted":"2017-11-13"},{"id":"b5e98bb1-6e21-409e-aed5-873db95ebeaf","acronym":"","url":"https://clinicaltrials.gov/study/NCT01951495","created_at":"2021-01-18T08:50:56.800Z","updated_at":"2024-07-02T16:37:16.669Z","phase":"Phase 2","brief_title":"A Study of Trametinib and GSK2141795 Multiple Myeloma","source_id_and_acronym":"NCT01951495","lead_sponsor":"University Health Network, Toronto","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • uprosertib (LAE003)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 10/01/2013","start_date":" 10/01/2013","primary_txt":" Primary completion: 10/01/2015","primary_completion_date":" 10/01/2015","study_txt":" Completion: 03/01/2016","study_completion_date":" 03/01/2016","last_update_posted":"2017-11-06"}]